-
Mashup Score: 4ESDO: esdo GI bullets - 23 day(s) ago
The addition of Pembrolizumab to perioperative chemotherapy increases the pCR rate, but does not improve the event-free survival (EFS) in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585). In a multicentre, randomised, placebo-controlled, phase III study, 1007 patients with locally advanced gastric or gastro-esophageal adenocarcinoma (≥cT3 i/lub N+) were randomly assigned to either the pembrolizumab plus perioperative chemotherapy group, or the placebo plus perioperative chemotherapy
Source: www.esdo.euCategories: General Medicine News, Hem/OncsTweet
RT @ESDO_tweets: Check out our Bulletin covering GI Oncology papers from 03/2024! 📢 @my_ueg https://t.co/1gA0Mix7H3 https://t.co/fEL7l70q34